Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
Abstract Background Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early stages of the disease, when participants are not cognitively impaired....
Main Authors: | Michelle M. Nuño, Daniel L. Gillen, Joshua D. Grill, for the Alzheimer’s Disease Cooperative Study |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-019-0544-6 |
Similar Items
-
Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
by: Mary M. Ryan, et al.
Published: (2019-10-01) -
Study partners should be required in preclinical Alzheimer’s disease trials
by: Joshua D. Grill, et al.
Published: (2017-12-01) -
Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
by: Olivia M. Bernstein, et al.
Published: (2021-01-01) -
Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
by: Emily A. Largent, et al.
Published: (2018-09-01) -
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
by: Jakub Sinsky, et al.
Published: (2021-08-01)